Biostem Technologies Stock Today
| BSEM Stock | USD 14.44 0.98 6.36% |
Performance9 of 100
| Odds Of DistressLess than 10
|
Biostem Technologies is selling at 14.44 as of the 22nd of December 2024; that is 6.36 percent decrease since the beginning of the trading day. The stock's lowest day price was 13.5. Biostem Technologies has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of December 2024. Click here to learn more.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. The company has 9.24 M outstanding shares. More on Biostem Technologies
Moving against Biostem OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Biostem OTC Stock Highlights
| Chairman | Jason Matuszewski |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Biostem Technologies [BSEM] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biostem Technologies's market, we take the total number of its shares issued and multiply it by Biostem Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Biostem Technologies conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 9.24 M outstanding shares.
Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.
Check Biostem Technologies Probability Of Bankruptcy
Biostem Technologies Risk Profiles
| Mean Deviation | 5.23 | |||
| Semi Deviation | 6.49 | |||
| Standard Deviation | 7.33 | |||
| Variance | 53.75 |
Biostem Stock Against Markets
Picking the right benchmark for Biostem Technologies otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Biostem Technologies otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Biostem Technologies is critical whether you are bullish or bearish towards Biostem Technologies at a given time. Please also check how Biostem Technologies' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Biostem Technologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Biostem Technologies Corporate Management
Elected by the shareholders, the Biostem Technologies' board of directors comprises two types of representatives: Biostem Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biostem. The board's role is to monitor Biostem Technologies' management team and ensure that shareholders' interests are well served. Biostem Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biostem Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Irmgard MD | International Officer | Profile | |
| Larry Jones | Chief Officer | Profile | |
| Michael CPA | Chief Officer | Profile | |
| David Woynarowski | Chief Officer | Profile |
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.